| Date | Price Target | Rating | Analyst |
|---|
Quantum-Si Incorporated, a company pioneering next-generation semiconductor chip-based proteomics, announced today the appointment of Marijn Dekkers, Ph.D. and Ruth Fattori to its Board of Directors. Both Dr. Dekkers and Ms. Fattori have agreed to continue to serve on the Board of Directors of the combined company subsequent to the closing of the previously announced business combination between Quantum-Si and HighCape Capital Acquisition Corp (NASDAQ:CAPA). "We are positioning Quantum-Si to have the best chance of delivering on the promise of next-generation proteomics by continuing to enhance our leadership team and board of directors, including the addition of Dr. Marijn Dekkers, former
Quantum-Si Incorporated, a company pioneering next-generation semiconductor chip-based proteomics, announced today the appointment of Michael Mina, M.D., Ph.D., Assistant Professor of Epidemiology, Immunology, Infectious Diseases and Pathology at the Harvard T.H. Chan School of Public Health and Harvard Medical School, as Chief Medical Advisor for the company. "As we create the next generation of protein sequencing and proteomics to transform how we study and diagnose disease, moving from the analog to the digital world and allowing a level of sensitivity, precision and understanding never before possible, Dr. Mina's expertise will be invaluable in guiding Quantum-Si's application efforts,
Cathie Wood’s Ark Investment Management on Friday bought 26,126 shares — estimated to be worth $163,026 — in Quantum-Si Inc (NASDAQ:QSI). Shares of the medical technology company closed 6.12% higher at $6.24 a share. The stock is down 40.5% year-to-date. Ark Invest has been piling up shares in the Guilford, Connecticut-based medical technology company via its flagship healthcare fund Ark Genomic Revolution ETF (BATS:ARKG). ARKG held 11.36 million shares — worth $66.8 million — in Quantum-Si ahead of Friday’s trade. The company went public earlier this year in a SPAC merger with HighCape Capital Acquisition Corp (NASDAQ:CAPA). Quantum-Si created the first next-gen protein sequencing pl
4 - Quantum-Si Inc (0001816431) (Issuer)
4 - Quantum-Si Inc (0001816431) (Issuer)
4 - Quantum-Si Inc (0001816431) (Issuer)
4 - Quantum-Si Inc (0001816431) (Issuer)
4 - Quantum-Si Inc (0001816431) (Issuer)
4 - Quantum-Si Inc (0001816431) (Issuer)
4 - Quantum-Si Inc (0001816431) (Issuer)
4 - Quantum-Si Inc (0001816431) (Issuer)
4 - Quantum-Si Inc (0001816431) (Issuer)
4 - Quantum-Si Inc (0001816431) (Issuer)
SC 13D - Quantum-Si Inc (0001816431) (Subject)
SC 13D - Quantum-Si Inc (0001816431) (Subject)
SC 13D/A - Quantum-Si Inc (0001816431) (Subject)
RALEIGH, NC / ACCESSWIRE / July 1, 2024 / Issuer Direct Corporation (NYSE:ISDR), an industry-leading communications company, today announced it has appointed Wes Pollard and Joe Staples as new independent members of its Board of Directors."We are excited to welcome Wes and Joe to the Issuer Direct Board of Directors," said CEO Brian Balbirnie. "We believe their respective skillsets are an ideal fit for us as we pursue our strategic vision to be a leading provider of media and communications software to the PR (Public Relations) and IR (Investor Relations) industry. We are confident they will be valuable additions to our company as we continue to optimize our business and work to maximize val
Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), a life science tools company commercializing a unique protein sequencing platform, announced today that they have expanded their Platinum early access program to ten sites, with participation from leading academic centers and key industry partners. The early access program introduces the Platinum single molecule sequencing system to key opinion leaders across the globe, for both expansion and development of applications and workflows. "The Company is experiencing tremendous momentum and demand for participation in our early access program to analyze previously unapproachable levels of biological understanding of t
Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si" or the "Company"), a company pioneering next-generation semiconductor chip-based proteomics, today announced its participation in the Cantor Fitzgerald Virtual Global Healthcare Conference which takes place September 27-30, 2021. John Stark, Quantum-Si's Chief Executive Officer, and Claudia Drayton, Chief Financial Officer, will participate in a virtual fireside chat on Wednesday, September 29, at 1:20 – 1:50 pm EDT. Please visit the Investor Relations section of the Quantum-Si website here to view the Company's most recent corporate presentation. About Quantum-Si Incorporated Founded by Dr. Jonathan Rothberg in 2013, Quantum-Si is focus
Quantum-Si Solidifies Financial Strength and Continues Systematic Commercialization Strategy Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si" or the "Company"), a company pioneering next-generation semiconductor chip-based proteomics, today announced financial results for the quarter ended June 30, 2021 and provided a business update. John Stark, Quantum-Si's Chief Executive Officer, and Claudia Drayton, Quantum-Si's Chief Financial Officer, will host a call today at 4:30 pm EDT to review the Company's results. Recent Highlights: Completed the business combination with HighCape Capital Acquisition Corp. ("HighCape"), adding over $511 million in cash to the balance sheet. Successfull
Quantum-Si Incorporated, a company pioneering next-generation semiconductor chip-based proteomics, today announced that it has rescheduled its conference call to report second quarter 2021 financial results to August 16, 2021, after market close. John Stark, Chief Executive Officer, and Claudia Drayton, Chief Financial Officer, will host a conference call and webcast at 4:30 p.m. ET on August 16, 2021, to discuss second quarter 2021 financial results and provide a business update. The conference call will be broadcast live in listen-only mode via a webcast on Quantum-Si's Investor Relations website at Events & Presentations. Individuals interested in listening to the conference call on y
Quantum-Si Incorporated, a company pioneering next-generation semiconductor chip-based proteomics, announced today that it has entered into a lease agreement with Phase 3 Real Estate Partners, Inc. to develop a 25,586-square-foot product development and operations facility in San Diego, CA. The new facility, located in Sorrento Mesa, is being designed to scale production and expand research and development efforts. We expect this site will play a vital role in expanding the company's recruitment efforts within our product development team as the company prepares for commercial readiness. The location was specifically selected due to its vast network of talent to support research and develo
GUILFORD, Conn. & NEW YORK--(BUSINESS WIRE)--Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSi” or “the Company”), a company pioneering next-generation semiconductor chip-based proteomics, today announced that it has completed its business combination with HighCape Capital Acquisition Corp. (Nasdaq: CAPA) (“HighCape”), a special purpose acquisition company sponsored by leading healthcare growth equity manager HighCape Capital LP. The business combination and concurrent private placement, which were approved by HighCape’s stockholders at its special meeting held on June 9, 2021, provide over $500 million to fund the further development and planned commercialization of the Com
NEW YORK, June 02, 2021 (GLOBE NEWSWIRE) -- HighCape Capital Acquisition Corp. (NASDAQ:CAPA) ("HighCape"), a special purpose acquisition company sponsored by leading healthcare growth equity investment firm HighCape Capital LP, reminds its stockholders of record as of the close of business on May 10, 2021 to vote at the upcoming special meeting of stockholders held virtually at https://www.cstproxy.com/highcape/sm2021 on June 9, 2021 at 10:00 a.m. Eastern Time (the "Special Meeting") to approve the proposed business combination with Quantum-Si Incorporated, a company pioneering next-generation semiconductor chip-based proteomics. The business combination cannot be completed unless (i) the
NEW YORK, May 27, 2021 (GLOBE NEWSWIRE) -- HighCape Capital Acquisition Corp. (NASDAQ:CAPA) ("HighCape"), a special purpose acquisition company sponsored by leading healthcare growth equity investment firm HighCape Capital LP, reminds its stockholders of record as of the close of business on May 10, 2021 to vote at the upcoming special meeting of stockholders held virtually at https://www.cstproxy.com/highcape/sm2021 on June 9, 2021 at 10:00 a.m. Eastern Time (the "Special Meeting") to approve the proposed business combination with Quantum-Si Incorporated, a company pioneering next-generation semiconductor chip-based proteomics. The business combination cannot be completed unless (i) the
NEW YORK and GUILFORD, Conn., May 17, 2021 (GLOBE NEWSWIRE) -- Quantum-Si Incorporated, a company pioneering next-generation semiconductor chip-based proteomics, and HighCape Capital Acquisition Corp. ("HighCape"), a healthcare-focused special purpose acquisition company (SPAC), today announced that the Securities and Exchange Commission ("SEC") has declared the Registration Statement on Form S-4 in connection with the proposed business combination between the two companies, to be effective. A special meeting of HighCape stockholders (the "Special Meeting") to approve, among other things, the proposed business combination, will be held in virtual format on June 9, 2021 at 10:00 a.m. Easte
Quantum-Si Solidifies Financial Strength and Continues Systematic Commercialization Strategy Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si" or the "Company"), a company pioneering next-generation semiconductor chip-based proteomics, today announced financial results for the quarter ended June 30, 2021 and provided a business update. John Stark, Quantum-Si's Chief Executive Officer, and Claudia Drayton, Quantum-Si's Chief Financial Officer, will host a call today at 4:30 pm EDT to review the Company's results. Recent Highlights: Completed the business combination with HighCape Capital Acquisition Corp. ("HighCape"), adding over $511 million in cash to the balance sheet. Successfull
Quantum-Si Incorporated, a company pioneering next-generation semiconductor chip-based proteomics, today announced that it has rescheduled its conference call to report second quarter 2021 financial results to August 16, 2021, after market close. John Stark, Chief Executive Officer, and Claudia Drayton, Chief Financial Officer, will host a conference call and webcast at 4:30 p.m. ET on August 16, 2021, to discuss second quarter 2021 financial results and provide a business update. The conference call will be broadcast live in listen-only mode via a webcast on Quantum-Si's Investor Relations website at Events & Presentations. Individuals interested in listening to the conference call on y
8-K - Quantum-Si Inc (0001816431) (Filer)
S-1 - Quantum-Si Inc (0001816431) (Filer)
8-K - Quantum-Si Inc (0001816431) (Filer)
8-K - Quantum-Si Inc (0001816431) (Filer)
8-K - Quantum-Si Inc (0001816431) (Filer)
8-K - Quantum-Si Inc (0001816431) (Filer)
25-NSE - HighCape Capital Acquisition Corp. (0001816431) (Subject)
10-Q/A - HighCape Capital Acquisition Corp. (0001816431) (Filer)
8-K - HighCape Capital Acquisition Corp. (0001816431) (Filer)
8-K - HighCape Capital Acquisition Corp. (0001816431) (Filer)